Celldex Therapeutics Inc (NASDAQ:CLDX) — Market Cap & Net Worth
Market Cap & Net Worth: Celldex Therapeutics Inc (CLDX)
Celldex Therapeutics Inc (NASDAQ:CLDX) has a market capitalization of $2.24 Billion ($2.24 Billion) as of June 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5947 globally and #1863 in its home market, demonstrating a 12.23% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Celldex Therapeutics Inc's stock price $32.12 by its total outstanding shares 78492072 (78.49 Million). Review total liabilities of Celldex Therapeutics Inc to assess the company's total debt and financial obligations.
Celldex Therapeutics Inc Market Cap History: 2015 to 2026
Celldex Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $18.46 Billion to $2.52 Billion (-15.91% CAGR).
Index Memberships
Celldex Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.09% | #143 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.01% | #652 of 3165 |
Weight: Celldex Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Celldex Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Celldex Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1421.23x
Celldex Therapeutics Inc's market cap is 1421.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.17 Billion | $6.79 Million | -$128.53 Million | 614.20x | N/A |
| 2017 | $3.34 Billion | $12.74 Million | -$93.03 Million | 262.40x | N/A |
| 2018 | $233.00 Million | $9.54 Million | -$151.18 Million | 24.43x | N/A |
| 2019 | $175.04 Million | $3.57 Million | -$50.88 Million | 48.99x | N/A |
| 2020 | $1.38 Billion | $7.42 Million | -$59.78 Million | 185.38x | N/A |
| 2021 | $3.03 Billion | $4.65 Million | -$70.51 Million | 652.10x | N/A |
| 2022 | $3.50 Billion | $2.36 Million | -$112.33 Million | 1484.26x | N/A |
| 2023 | $3.11 Billion | $6.88 Million | -$141.43 Million | 452.27x | N/A |
| 2024 | $1.98 Billion | $7.02 Million | -$157.86 Million | 282.55x | N/A |
| 2025 | $2.13 Billion | $1.50 Million | -$258.80 Million | 1421.23x | N/A |
Competitor Companies of CLDX by Market Capitalization
Companies near Celldex Therapeutics Inc in the global market cap rankings as of June 16, 2026.
Key companies related to Celldex Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Celldex Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Celldex Therapeutics Inc's market cap moved from $18.46 Billion to $ 2.52 Billion, with a yearly change of -15.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.52 Billion | +18.26% |
| 2025 | $2.13 Billion | +7.48% |
| 2024 | $1.98 Billion | -36.28% |
| 2023 | $3.11 Billion | -11.02% |
| 2022 | $3.50 Billion | +15.35% |
| 2021 | $3.03 Billion | +120.55% |
| 2020 | $1.38 Billion | +685.65% |
| 2019 | $175.04 Million | -24.88% |
| 2018 | $233.00 Million | -93.03% |
| 2017 | $3.34 Billion | -19.77% |
| 2016 | $4.17 Billion | -77.42% |
| 2015 | $18.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Celldex Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.24 Billion USD |
| MoneyControl | $2.24 Billion USD |
| MarketWatch | $2.24 Billion USD |
| marketcap.company | $2.24 Billion USD |
| Reuters | $2.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more